Cargando…
Tumor immunology Volume 130 /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cambridge, UK :
Academic Press is an imprint of Elsevier,
2016.
|
| Colección: | Advances in immunology ;
v. 130. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
Tabla de Contenidos:
- Front Cover; Tumor Immunology; Copyright; Contents; Contributors; Preface; Chapter One: Mouse Models of Tumor Immunotherapy; 1. Introduction; 2. Transplantable Tumor Models; 3. Genetically Engineered Tumor Models; 4. Carcinogen-Induced Tumor Models; 5. Humanized Mouse Tumor Models; 6. Perspectives; 7. Materials and Methods; 7.1. BALB/c MMTV-Her2 Mammary Carcinoma; 7.2. MCA-Induced Fibrosarcoma; Acknowledgments; References; Chapter Two: The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer; 1. Introduction
- 2. Cancer Immunoediting as an Encompassing Model of Immune System-Tumor Interactions2.1. Elimination; 2.2. Equilibrium; 2.3. Escape; 3. Antigenic Targets of Cancer Immunoediting; 4. Setting the Groundwork: Genomic Approaches to Cancer Antigen Identification; 5. Developing Cancer Immunotherapies Based on Genomic Identification of Tumor-Specific Neoantigens; 5.1. Epitope Prediction Algorithms; 5.2. Retrospective Bioinformatic Analyses of Previously Identified Cancer Neoantigens
- 5.3. Experimental Evidence from Preclinical Cancer Models That Neoantigens Form the Basis for Effective Personalized Canc...6. Neoantigens as Therapeutic Targets in HumanCancer; 6.1. Neoantigens in Adoptive Cellular Therapy in Humans; 6.2. Neoantigens as Targets of Tcells Activated by Checkpoint Blockade in Humans; 6.3. The Use of Neoantigen Cancer Vaccines in Humans; 7. Concluding Remarks; Acknowledgments; References; Chapter Three: Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
- 5. Germline Genetic Differences as an Additional Source of Interpatient Heterogeneity6. Conclusions and Implications; References; Chapter Four: Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Class ...; 1. Introduction; 1.1. Control of Cancer Growth Through Adaptive Immunity; 1.1.1. Immunosurveillance of Cancer; 1.1.2. Tumor Antigens; 1.1.3. Tumor Control by the Tumor Microenvironment (TME); 1.2. Inflammation and Cancer; 1.2.1. Inflammation Promotes Carcinogenesis; 1.2.2. Inflammatory Mediators Promote Cell Survival and Cell Proliferation